To gain trust from medical and regulatory teams, AI companies must move beyond being 'tech demos.' The key is to build solutions as medical products with transparent validation, reproducible results, and deep integration into existing clinical workflows. Trust is earned through reliability over time, not just peak performance on a single dataset.

Mathematical explainability approaches like SHAP values and ablation studies are insufficient to build trust with clinical experts. Life sciences models must generate qualitative reasoning traces that mirror clinical rationale, which can then be validated against subject matter expertise to confirm sound decision-making.

Just as GXP compliance doesn't require mapping a human's brain, AI governance shouldn't fixate on fully explaining a model's "black box." Instead, it should mimic human compliance by establishing robust frameworks around the model—controlling inputs, outputs, traceability, and guardrails—to ensure trustworthy outcomes.

In a skeptical, regulated industry, simply predicting an outcome is insufficient. Causal AI is non-negotiable because it provides a 'glass box' explanation for its recommendations. It connects outputs to data points and biological reasoning, satisfying the critical 'why' questions from both sponsors and regulators.

For AI systems to be adopted in scientific labs, they must be interpretable. Researchers need to understand the 'why' behind an AI's experimental plan to validate and trust the process, making interpretability a more critical feature than raw predictive power.

To overcome the "black box" problem in medical AI, Effion Health provides clinicians with a dashboard that reveals the specific parameters used to calculate its biomarker score. This transparency allows doctors to understand the AI's reasoning, fostering the trust required for confident clinical decision-making.

AI software represents a costly operational risk if vendors cannot explain how their underlying models arrive at specific conclusions. Sponsors and CROs must push beyond demonstrations to ensure vendor systems can cite grounded rationale before deployment in regulated workflows.

The FDA approved Artera AI’s prostate cancer diagnostic without understanding *why* it works. This precedent suggests that massive retrospective validation on patient data can substitute for model interpretability, changing the strategic focus for medical AI companies.

Achieving explainability in AI for drug development isn't about post-hoc analysis. It requires building models from the ground up using inherently interpretable data like RNA sequencing and mutational profiles. When the inputs are explainable, the model's outputs become explainable by design.